Recently, in the results of a phase I study, 20 children and adults (aged 2–43 years) with relapsed/remitting T-ALL were given allogeneic donor-derived anti-CD7 CAR-T-cells. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.